Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.
Times cited: 15
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
New England Journal of Medicine.
Times cited: 583